NUMERO: #20240084

Título: USE OF BOTULINUM TOXIN IN PATIENTS IN THE INTENSIVE CARE UNIT: RETROSPECTIVE ANALYSIS FROM JANUARY 2022 TO JULY 2023

Nome do Apresentador: Taciane Leite REZENDE

Categoria do Trabalho: Painel de pesquisa científica (PPC)

Área Temática: Odontologia hospitalar

Resumo: Botulinum Toxin is a neurotoxin produced by the bacterium Clostridium Botulinum, which serves both aesthetic and functional purposes. In intensive therapy, it is common for patients to present with drooling associated with dysphagia and oromandibular dystonia, making the application of botulinum toxin advantageous in these cases. The objective is to profile patients who are indicated for botulinum toxin application in the ICU. An observational, cross-sectional, retrospective, and descriptive study was conducted on patients admitted to ICU beds from January 2022 to July 2023. One hundred patients were selected who had indications for botulinum toxin application for drooling and oromandibular dystonias, evaluated by the dental team. It was observed that patients with neurological sequelae benefit from the toxin, representing 76% of the total cases, with Traumatic Brain Injury being the most prevalent (33% of cases), and the use of botulinum toxin in ICU patients ensured safety during hospitalization, reduced hospital complications, and improved quality of life. Of botulinum toxin in ICU patients presents numerous benefits for dystonias, drooling, and dysphagia.

Autor 1:  Taciane Leite REZENDE

E-mail 1:  [email protected]

Autor 2:   Stephanie Ferreira VILAS BOAS

E-mail 2:  [email protected]

Autor 3 :  Paula Ferreira de ANDRADE

E-mail 3:  [email protected]

Autor 4:  Priscila Fernandes RIBAS

E-mail 4:  [email protected]

Autor 5:  Diogo Toledo MATIAS

E-mail 5:  [email protected]

Autor 6:  Maria Paula Siqueira de Melo PERES

E-mail 6:  [email protected]

Autor 7:  Juliana Bertoldi FRANCO

E-mail 7:  [email protected]